Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2022; 28(48): 6888-6899
Published online Dec 28, 2022. doi: 10.3748/wjg.v28.i48.6888
Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
Yi-Han Xu, Wei-Ming Zhu, Zhen Guo
Yi-Han Xu, Wei-Ming Zhu, Zhen Guo, Department of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China
Author contributions: Xu YH and Guo Z performed the majority of the writing and the table; Zhu WM designed the outline and coordinated the writing of the paper; and all authors have read and approve the final manuscript.
Supported by Jiangsu Provincial Health Commission, No. M2021013; and the Science Foundation of Jinling Hospital, No. YYMS2021035.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen Guo, MD, PhD, Professor, Department of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, No. 305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China. guozhi0809@sina.com
Received: September 13, 2022
Peer-review started: September 13, 2022
First decision: November 5, 2022
Revised: November 11, 2022
Accepted: December 1, 2022
Article in press: December 1, 2022
Published online: December 28, 2022
Processing time: 104 Days and 21.3 Hours
Core Tip

Core Tip: The emergence of biologics and small molecules has significantly changed the therapies used for inflammatory bowel disease (IBD). However, the efficacy of these drugs is not satisfactory for every patient, which indicates an unmet need for optimizing the use of biologics/small molecules and for predicting therapeutic responses. Here, we describe the current status of novel biologics and small molecules and new treatment strategies to combat IBD by using more than one biologic.